Triflusal

Triflusal
Clinical data
ATC code	B01AC18 (WHO) ;
Identifiers
	IUPAC name 2-acetyloxy-4-(trifluoromethyl)benzoic acid;
PubChem CID	9458;
CompTox Dashboard (EPA)	DTXSID8045305 ;
ECHA InfoCard	100.005.726
Chemical and physical data
Formula	C10H7F3O4
Molar mass	248.155 g/mol g·mol−1

Triflusal is a platelet aggregation inhibitor that was discovered and developed in the Uriach Laboratories, and commercialised in Spain since 1981. Currently, it is available in 25 countries in Europe, Asia, Africa and America. It is a drug of the salicylate family but it is not a derivative of acetylsalicylic acid (ASA). Trade name includes Disgren, Grendis, Aflen and Triflux<ref>Murdoch D, et al. Triflusal: a review of its use in cerebral infarction and myocardial infarction, and as thromboprophylaxis in atrial fibrillation. Drugs 2006; 66 (5):671-92 Cite error: The opening <ref> tag is malformed or has a bad name (see the help page).

Mechanism of Action

bl

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.